IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Provides Update on Data Linking THC to Decrease in Aß40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aß40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aß plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical studies at USF’s College of Pharmacy, led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” In the news release, Ram Mukunda, CEO of IGC, stated, “IGC acquired the exclusive right to this patent filing and we plan to advance this technology through medical trials that can potentially bring much needed relief for patients suffering from AD.”

To view the full press release, visit http://nnw.fm/cG8Dj

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us